{"id":"meningitectm","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine consists of meningococcal serogroup C polysaccharide conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows for improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by serogroup C.","oneSentence":"Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroup C polysaccharide capsule.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:43.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"}]},"trialDetails":[{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MeningitecTM","genericName":"MeningitecTM","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroup C polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}